Tremelimumab No Match vs Metastatic Melanoma Standard of Care

The anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody tremelimumab failed to achieve a significant improvement in survival among patients with metastatic melanoma compared with the standard of care treatments used in the comparator arm, according to the results of a phase III study.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news